Table 1.
Therapy interruption patterns among295 same-day outpatient dermatology consultations for acute dermatologic adverse events (dAEs)in patients receiving systemic oncologic treatment within 30 days pre-consultation
| Anticancer therapy interruption by
referring clinician |
||
|---|---|---|
| Yesn = 73 (25) | Non = 222 (75) | |
| Age median [range] | 58 [17–87] | 58 [13–85] |
| Sex (female) | 42 (58) | 136 (61) |
| Race | ||
| White | 43 (59) | 163 (73) |
| Asian | 11 (15) | 17 (8) |
| Black | 9 (12) | 20 (9) |
| Other | 10 (14) | 22 (10) |
| Primary cancer | ||
| Breast | 20 (27) | 75 (34) |
| Gastrointestinal | 13 (18) | 31 (14) |
| Hematologic# | 12 (16) | 30 (14) |
| Lung | 7 (10) | 23 (10) |
| Gynecologic | 6 (8) | 7 (3) |
| Genitourinary | 6 (8) | 25 (11) |
| Soft tissue sarcoma | 3 (4) | 8 (4) |
| Skin | 3 (4) | 7 (3) |
| Neurological | 1 (1) | 5 (2) |
| Head and neck | 0 (0) | 5 (2) |
| Other^ | 2 (3) | 6 (3) |
| Anticancer therapy* | ||
| Targeted## therapy | 24 (33) | 53 (24) |
| Cytotoxic chemotherapy | 22 (30) | 76 (34) |
| Combination therapy | 19 (26) | 67 (30) |
| Immunotherapy | 6 (8) | 10 (5) |
| Other& | 2 (3) | 16 (7) |